← All trials
NCT00121550
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1999
- Primary completion
- Apr 1, 2000
- Completion date
- Sep 1, 2002
- First posted
- —
- Last posted
- —
- Enrollment
- 4372
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CopenhagenLead sponsor
- The 1991 Pharmacy FoundationCollaborator
- University of CopenhagenCollaborator
- Government of DenmarkCollaborator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenStudy chair
- Danish Heart FoundationCollaborator
- AbbottCollaborator
- University of CopenhagenReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.